21
Feb

Life sciences briefing: Thursday, Feb. 21, 2008

Posted by: David P. Hamilton
in lifesciences, deal, medical devices, biotechnology, inv:kleiner perkins, 3i Group, co:Accumetrics, co:TherOx, co:Zonare Medical Systems, diagnostics, heart attack, inv:Arnerich Massena & Associates, inv:Ascension Health Ventures, inv:BBT Fund, inv:CB Health Ventures, inv:Draper Fisher Jurvestson, inv:Earlybird, inv:Essex Woodland Health Ventures, inv:Frazier Healthcare Ventures, inv:Integral Capital Partners, inv:Kaiser Permanente Ventures, inv:KB Partners, inv:Merrill Lynch Venture Capital, inv:Mosaix Ventures, inv:New Science Ventures, inv:PTV Sciences, inv:RiverVest, inv:saints, inv:Texas Instruments, medical imaging, oxygen therapy, personalized medicine, ultrasound

TODAY’S HEADLINES:

zonare-logo.gifCompact ultrasound maker Zonare Medical raises $30M – Zonare Medical Systems, a Mountain View, Calif., maker of ultrasound-imaging systems, raised $30 million in a recent seventh funding round, VentureWire reports. Existing investors provided the funding, a group that includes Frazier Healthcare Ventures, 3i Group, Mosaix Ventures, CB Health Ventures, Draper Fisher Jurvestson, Ascension Health Ventures, Kaiser Permanente Ventures, Earlybird, Saints Capital, Merrill Lynch Venture Capital and Texas Instruments.

The company said the funding should set it on the road to profitability and eventually to a hope-for IPO. Zonare makes compact ultrasound systems that can be used in sonography and for a variety of other medical diagnostic purposes.

therox-logo-150px.gifTherOx raises $30M for hypersaturated-oxygen devices – TherOx, an Irvine, Calif., maker of oxygenation devices for treating heart attacks, raised $30 million in a tenth funding round, peHUB reports. Investors included Kleiner Perkins, Integral Capital Partners and New Science Ventures.

The startup makes devices that supersaturate blood with oxygen, then infuse that blood into areas of the heart at risk of damage from oxygen starvation due to a heart attack. TherOx has now raised over $120 million in venture funding.

accumetrics-logo-150px.gifAccumetrics, antiplatelet-drug diagnostic maker, raises $29M – San Diego’s Accumetrics, a maker of diagnostics that measure patient response to anti-platelet drugs, raised $28.8 million in a fourth round of funding. Investors included Arnerich Massena & Associates, BBT Fund, Essex Woodland Health Ventures, RiverVest, PTV Sciences, KB Partners and Kaiser Permanente Ventures.

The startup makes a system that measures how well individuals are reacting to treatment with anti-platelet drugs, which are used to prevent or help dislodge major blood clots. Since patient response can vary widely, often as a result of genetic factors (see our coverage of this sort of “personalized medicine” here), such monitoring can help doctors avoid dangerous overdoses or to switch unresponsive patients to higher doses or different drugs as necessary.

No user resposed " Life sciences briefing: Thursday, Feb. 21, 2008 "

"Life sciences briefing: Thursday, Feb. 21, 2008" was posted by David P. Hamilton and received no user commented
Welcome stranger, please leave your commnets below

  Username (required)

  Email (required)

  Website

leave your comments below

Subsribes to this topic Comment Rss or TrackBack

about

SocialTake.com brings you the latest social networking and web 2.0 news from the most popular sources on the web.

categories

meta

calendar

February 2008
M T W T F S S
« Jan   Mar »
 123
45